Axicabtagene ciloleucel - Biologic Drug Details

Summary for axicabtagene ciloleucel

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	1
Recent Clinical Trials:	See clinical trials for axicabtagene ciloleucel

Recent Clinical Trials for axicabtagene ciloleucel

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Ruijin Hospital	PHASE2
City of Hope Medical Center	PHASE2
National Cancer Institute (NCI)	PHASE2

See all axicabtagene ciloleucel clinical trials

Pharmacology for axicabtagene ciloleucel

Mechanism of Action	CD19 Receptor Interactions
Physiological Effect	Increased T Lymphocyte Activation
Established Pharmacologic Class	CD19-directed Chimeric Antigen Receptor Genetically-modified Autologous T Cells
Chemical Structure	CD19-specific Chimeric Antigen Receptor

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for axicabtagene ciloleucel Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for axicabtagene ciloleucel Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Kite Pharma Inc.	YESCARTA	axicabtagene ciloleucel	Injection	125643	10,125,191	2037-08-11	DrugPatentWatch analysis and company disclosures
Kite Pharma Inc.	YESCARTA	axicabtagene ciloleucel	Injection	125643	10,316,089	2036-08-09	DrugPatentWatch analysis and company disclosures
Kite Pharma Inc.	YESCARTA	axicabtagene ciloleucel	Injection	125643	10,370,460	2036-05-19	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for axicabtagene ciloleucel Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Kite Pharma Inc.	YESCARTA	axicabtagene ciloleucel	Injection	125643	11,332,451	2040-09-16	Patent claims search

International Patents for axicabtagene ciloleucel

Country	Patent Number	Estimated Expiration
European Patent Office	2726882
New Zealand	754886
Japan	7102075

Market Dynamics and Financial Trajectory for Axicabtagene Ciloleucel

Last updated: February 15, 2026

Overview

Axicabtagene ciloleucel (marketed as Yescarta) is a CAR T-cell therapy approved for relapsed or refractory large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL), primary mediastinal B-cell lymphoma, and transformed follicular lymphoma. Since its FDA approval in October 2017, the therapy has become a key player in personalized oncology, driven by unmet medical needs and a significant market potential.

Market Size and Growth Drivers

• Global Blood Cancer Incidence: In 2022, approximately 81,000 new cases of non-Hodgkin lymphoma (NHL) occurred in the U.S., with DLBCL constituting 30-40% of cases [1].

• Market Value: As of 2022, the global CAR T-cell therapy market was valued at USD 1.3 billion, projected to grow at a CAGR of 20% through 2030, reaching USD 7.2 billion [2].

• Key Drivers:

  • Increasing approval of CAR T therapies for various hematologic malignancies expands indications.
  • Evolving treatment guidelines positioning CAR T therapies as second-line options for aggressive lymphomas.
  • Growing adoption in developed markets, supported by healthcare infrastructure.
  • Rising incidence of lymphomas globally, especially in aging populations.

Competitive Landscape and Market Position

• Primary competitors include Novartis's tisagenlecleucel (Kymriah) and Bristol-Myers Squibb's (BMS) lisocabtagene maraleucel (Breyanzi).

• Market Share (2022 estimates):

  • Yescarta: 45%
  • Kymriah: 35%
  • Breyanzi: 15%
  • Others (e.g., Tecartus): 5%

• Differentiators:

  • Yescarta was the first CAR T approved for LBCL.
  • Variations in manufacturing processes, dosing, and safety profiles influence clinician choice.

Regulatory Actions and Expanding Indications

• FDA Approvals:

  • 2017: For adult LBCL after two prior therapies.
  • 2020: Expanded into second-line therapy (with ZUMA-7 trial data).
  • 2022: Approved for relapsed or refractory LBCL in pediatric and young adult populations.

• Regulatory Approvals in Country Markets:

  • European Medicines Agency (EMA): Approved in 2018.
  • Japan: Approved in 2019.

• Emerging indications and accelerated approvals signal growth opportunities.

Pricing and Reimbursement

• Price Point:

  • List price in the U.S.: USD 373,000 per infusion [3].

• Cost Considerations:

  • Total treatment cost with hospital stay, management of side effects, and outpatient care exceeds USD 500,000.
  • Reimbursement hinges on value-based agreements, especially in the U.S., with payers requesting outcome-based pricing.

• Market Access Challenges:

  • High costs limit accessibility.
  • Reimbursement policies vary across countries, affecting global penetration.

Financial Performance and Revenue Trends

• Historical Revenue:

  • 2019: USD 230 million.
  • 2021: USD 680 million, reflecting increased adoption and expanded indications.
  • 2022: USD 950 million, with growth driven by geographic expansion and second-line approvals.

• Forecasted Revenue:

  • By 2025, revenues could approach USD 2.5 billion, assuming continued market penetration and expanded indications.
  • Key factors include:
  • Additional approvals in earlier treatment lines.
  • Entry into new indications (e.g., follicular lymphoma).
  • Competition influencing market share distribution.

Operational and Manufacturing Considerations

• Supply Chain:

  • Manufacturing relies on autologous T-cell harvesting, processing, and reinfusion.
  • Capacity expansions are underway to meet rising demand, with some companies exploring allogeneic “off-the-shelf” options to reduce costs and improve availability.

• Reimbursement and Cost Management:

  • Payers favor outcome-based reimbursement models, linking payments to treatment durability and patient response.
  • Manufacturers invest in post-market studies to validate long-term efficacy, impacting future revenues.

Regulatory and Market Challenges

• Safety Profile Concerns:

  • Cytokine release syndrome (CRS) and neurotoxicity are significant adverse events; management protocols are established.

• Manufacturing Delays:

  • Logistical challenges and production timelines can limit patient access, affecting revenue realization.

• Market Competition:

  • New CAR T therapies and alternative treatments threaten market share.
  • Innovations in gene editing and allogeneic approaches could disrupt current dynamics.

Strategic Implications

• Expansion of Indications:

  • Efforts to secure approvals for earlier lines and additional lymphoma subtypes.

• Pipeline Development:

  • Investment in next-generation CAR T-cell therapies aims to improve safety, efficacy, and manufacturing efficiency.

• Pricing Strategies:

  • Value-based reimbursement models are critical to sustaining revenue streams.

Conclusion

Axicabtagene ciloleucel maintains a dominant position within CAR T-cell therapies for LBCL, with revenues approaching USD 1 billion in 2022 and potential to exceed USD 2.5 billion by 2025. Growth hinges on expanding indications, managing costs, maintaining safety profiles, and navigating competitive and regulatory landscapes.

---

Key Takeaways

• The global CAR T-cell therapy market is set to grow at a CAGR of 20%, driven by increased approvals, expanding indications, and rising lymphoma incidence.
• Axicabtagene ciloleucel accounts for nearly half of the current CAR T market share, with revenues near USD 1 billion in 2022.
• Revenue expansion depends on securing second-line approvals, geographic expansion, and managing manufacturing logistics.
• Pricing remains high, with USD 373,000 list prices, and reimbursement policies are evolving toward outcome-based models.
• Competition and technological advancements may influence market share and long-term financial performance.

---

FAQs

1. What are the main indications for axicabtagene ciloleucel approval?

   A: It is approved for relapsed or refractory large B-cell lymphoma, including DLBCL, primary mediastinal B-cell lymphoma, and transformed follicular lymphoma.

2. How does the pricing of Yescarta compare to other CAR T therapies?

   A: The list price is approximately USD 373,000 per infusion, with total treatment costs exceeding USD 500,000, which is comparable to other CAR T products like Kymriah and Breyanzi.

3. What factors influence the revenue growth of axicabtagene ciloleucel?

   A: Approvals for earlier lines of therapy, geographic expansion, manufacturing capacity, reimbursement policies, and competition are key factors.

4. What are the main challenges facing the commercialization of CAR T therapies?

   A: Manufacturing delays, high costs, safety concerns (CRS and neurotoxicity), and reimbursement hurdles.

5. What is the outlook for the CAR T-cell therapy market through 2030?

   A: Expected to grow significantly, driven by new indications, technological innovations, and market expansion, reaching an estimated USD 7.2 billion globally.

---

References

[1] National Cancer Institute. Non-Hodgkin’s Lymphoma Statistics. 2022.

[2] MarketsandMarkets. CAR T-cell Therapy Market by Application, Region - Global Forecast to 2030. 2022.

[3] Bloomberg Industry Reports. CAR T-cell Therapy Pricing and Reimbursement Trends. 2022.